Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
January 15, 2007
- OPINION
January 15, 2007
- Burgeoning Market for ARBs -Hot Battlefield for Megapharmas-
January 15, 2007
- Constipation Does Not Increase Risk of Colorectal Cancer: Korosho Study Group
January 15, 2007
- Korosho Committed to Promoting Innovation in Pharma Industry: Health Minister
January 15, 2007
- Bile Acid Reflux Causes Gastric Ulcers, Cancer: Prof. Haruma
January 15, 2007
- FPMAJ to Propose New Drug Pricing Rule: President Morita
January 15, 2007
- NPhA to Focus on Its Incorporation, Increase in Membership
January 15, 2007
- STATISTICS
January 8, 2007
- 72% of Smokers Unaware of Insurance Coverage for Smoking Cessation: Novartis
January 8, 2007
- Mr Uchida of ABMJ Expresses High Expectations of Vaccine Study Group
January 8, 2007
- Metabolic Syndrome, Not Alcohol Consumption, Contributes to ALT Elevation
January 8, 2007
- R&D NEWS IN BRIEF
January 8, 2007
- Japan Ranks 5th Among OECD Countries in Health: JPC-SED
January 8, 2007
- JACDS to Review Relationship with JPA
January 8, 2007
- Drug Industry in Japan Has Wind at Its Back
January 8, 2007
- Most Medical Institutions Leery of Generics Despite Increased Use
January 8, 2007
- Shionogi, DSP to Enter ARB Market with Irbesartan
January 8, 2007
- Generic Entry Should Be Permitted in the Absence of Original Products: Ihoken
January 8, 2007
- Sales to Break \80 Bil. in 2006: Schering-Plough
January 8, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…